Vericel Corporation

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Vericel Corporation sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials 2 currently recruiting 8 completed top decile by trial count

Vericel Corporation: 11 sponsored US clinical trials, 2 recruiting.

Vericel Corporation sponsors 11 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Articular Cartilage Defect, with 2 trials.

Top-decile sponsor footprint

Vericel Corporation ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

11 total, page 1 of 1

RECRUITING Phase 3

A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

NCT06915233
RECRUITING Phase 3

A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

NCT03588975
COMPLETED Phase 2

An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)

NCT01670981
COMPLETED Phase 3

An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI)

NCT01483898
COMPLETED Phase 2

Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy

NCT01020968
COMPLETED Phase 2

Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

NCT00765518
COMPLETED Phase 3

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

NCT00505219
COMPLETED Phase 2

Use of Ixmyelocel-T (Formerly Vascular Repair Cells [VRC]) in Patients With Peripheral Arterial Disease to Treat Critical Limb Ischemia

NCT00468000
TERMINATED Phase 1

Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.

NCT00424567
COMPLETED Phase 4

Study of the Treatment of Articular Repair (STAR)

NCT00158613
COMPLETED

The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients

NCT00140634

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 4
Phase 3 4
Phase 4 1

Therapeutic Areas

Articular Cartilage Defect 2
Chondral Defect 2
Articular Cartilage Disorder of Knee 1
Osteochondritis Dissecans (OCD) 1
Critical Limb Ischemia 1
Dilated Cardiomyopathy 1
Peripheral Arterial Disease 1

What is open in the Vericel Corporation pipeline

2 recruiting of 11 indexed (18% open); 8 completed (73%).

Phase mix: 5 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Articular Cartilage Defect (2 trials), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Vericel Corporation: open-pipeline peers nationwide

Peers matched on 11 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Vericel Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10.910.91111.1 0%5%10%15%20% Total trials Recruiting share Vericel CorporationAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiomeBurke Medical Research InstituteGrand Valley State UniversityImunonInventisBio Co.
Vericel Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Vericel Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Vericel Corporation page

11 registered trials is a research-attention snapshot, not an endorsement of Vericel Corporation or any single study.

  • 2 of Vericel Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Articular Cartilage Defect is the condition Vericel Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Articular Cartilage Defect trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Vericel Corporation pipeline card: 11 registered trials from official public datasets.Report a data error.